In the latest quarter, 15 analysts provided ratings for Moderna (NASDAQ:MRNA), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 9 | 2 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 1 | 2 | 5 | 1 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $85.4, a high estimate of $139.00, and a low estimate of $55.00. A decline of 22.58% from the prior average price target is evident in the current average.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Moderna. The...
Login or create a forever free account to read this news
Sign up/Log in
